Jan 08, 2024 / 04:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott, pharma analyst at JPMorgan. And it's my pleasure to be introducing Teva today.
From the company we have CEO, Richard Francis. Richard joined Teva roughly a year ago. The company has had a very productive 2023 and looking forward to hearing about the setup for Teva going forward.
So with that, Richard, thanks for joining us. And we'll jump to Q&A after your presentation.
Richard D. Francis - Teva Pharmaceutical Industries Limited - President, CEO & Director
Thanks very much, Chris. Good morning, everybody. Delighted to be here. Yes, it's been One year, one hell of a year, where I think that the work we've done at Teva has really transformed Teva, quite a bit of change and put us on the path for continuous growth going forward. So very excited about that.
And let me walk you through a bit of what's given me that optimism and some of the progress we've made in that first year. So when I was here last
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers